Lecanemab clinical trials, in English

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

NCT05925621 · Official ClinicalTrials.gov record · Beth Israel Deaconess Medical Center

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

NCT06322667 · Official ClinicalTrials.gov record · Eisai Co., Ltd.

The goal of this clinical trial is to To demonstrate the Safety and how well it works of dcLVA Surgery for the Treatment of Alzheimer's Disease. Patients who meet the inclusion and who cannot join and consent to participate will be randomly assigned to either the experimental group (receiving dcLVA surgery plus standard medication) or the control group (receiving standard medication alone) Participants will: Undergo cognitive assessment and brain MRI assessment; Undergo a lumbar puncture; Undergo an injection of 20ml of gadodiamide contrast agent at a concentration of 0.5 mmol/L (1ml gadodiamide: 20ml 0.9% saline).

NCT06530732 · Official ClinicalTrials.gov record · Zhejiang Provincial People's Hospital

As the population increases and aging intensifies, cognitive disorders represented by Alzheimer's disease (AD) not only pose a severe threat to public health but also bring significant social and economic burdens. Previously, treatment options for Alzheimer's disease were very limited, mainly providing symptomatic relief with few available medications.

NCT06741553 · Official ClinicalTrials.gov record · Second Affiliated Hospital, Zhejiang University, School of Medicine

Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families.

NCT06871839 · Official ClinicalTrials.gov record · Cuibai Wei，Clinical Professor

The goal of this watch-and-measure (no experimental treatment required) study is to learn about the how well it works of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing.

NCT06883019 · Official ClinicalTrials.gov record · RenJi Hospital

The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to measure the impact of these new therapies and diagnostic techniques in clinical practice.

NCT06889818 · Official ClinicalTrials.gov record · Ewha Womans University Mokdong Hospital

The goal of this study is to explore the how well it works and safety of near-infrared light combined with lecanemab in patients with mild Alzheimer's disease (AD). This study will employ a randomly assigned, neither you nor the study doctors know who gets the real treatment, sham-controlled method with an open-label extension phase.

NCT06992804 · Official ClinicalTrials.gov record · Xuanwu Hospital, Beijing

The goal of this watch-and-measure (no experimental treatment required) study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects treated with lencanumab.

NCT07153848 · Official ClinicalTrials.gov record · First Affiliated Hospital of Zhejiang University

This research proposal outlines a multi-center, randomly assigned, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited.

NCT07604896 · Official ClinicalTrials.gov record · First Affiliated Hospital of Wenzhou Medical University

This study aims to measure the therapeutic how well it works of Lecanemab in patients with Alzheimer's disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced electrochemiluminescence (ECL) to monitor specific biomarkers in the patients' plasma.

NCT07688460 · Official ClinicalTrials.gov record · The Fourth Affiliated Hospital of Zhejiang University School of Medicine

To describe the incidence and severity of known side effects, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy \[CAA\]). The secondary purpose of this study is, To describe progression to the next stage of Alzheimer's Disease (AD), stratified by ARIA and intracerebral hemorrhage greater than 1 cm.

NCT07762092 · Official ClinicalTrials.gov record · Eisai Limited

The primary purpose of this study is to measure the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 cm in participants treated with lecanemab-irmb. The secondary purpose of this study is to: measure the safety of lecanemab-irmb in the real-world clinical setting as reported by events of seizures, anaphylaxis, central nervous system (CNS) ischemic event, and death.

NCT07821658 · Official ClinicalTrials.gov record · Eisai Inc.